In addition, this study highlights the regulatory role of HSP-Exs in the tumor immune microenvironment (TIME) and explores the potential advantages and limitations of using HSP-Exs as next-generation tumor vaccines in the context of current clinical cancer therapies. This evidence concerns the gene HSP90B2P and neoplasm.